- Home
- KOD vs PSBD Comparison
KOD vs PSBD Comparison
Compare KOD & PSBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- PSBD
- Stock Information
- Founded
- KOD 2009
- PSBD 2009
- Country
- KOD United States
- PSBD United States
- Employees
- KOD N/A
- PSBD N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- PSBD
- Sector
- KOD Health Care
- PSBD
- Exchange
- KOD Nasdaq
- PSBD Nasdaq
- Market Cap
- KOD 454.7M
- PSBD 519.7M
- IPO Year
- KOD 2018
- PSBD 2024
- Fundamental
- Price
- KOD $7.50
- PSBD $15.75
- Analyst Decision
- KOD Hold
- PSBD Buy
- Analyst Count
- KOD 4
- PSBD 7
- Target Price
- KOD $8.00
- PSBD $16.93
- AVG Volume (30 Days)
- KOD 448.1K
- PSBD 17.7K
- Earning Date
- KOD 11-14-2024
- PSBD 02-08-2025
- Dividend Yield
- KOD N/A
- PSBD 12.02%
- EPS Growth
- KOD N/A
- PSBD N/A
- EPS
- KOD N/A
- PSBD N/A
- Revenue
- KOD N/A
- PSBD N/A
- Revenue This Year
- KOD N/A
- PSBD N/A
- Revenue Next Year
- KOD N/A
- PSBD N/A
- P/E Ratio
- KOD N/A
- PSBD N/A
- Revenue Growth
- KOD N/A
- PSBD N/A
- 52 Week Low
- KOD $2.19
- PSBD $15.12
- 52 Week High
- KOD $11.60
- PSBD $17.12
- Technical
- Relative Strength Index (RSI)
- KOD 44.49
- PSBD 52.81
- Support Level
- KOD $7.21
- PSBD $15.17
- Resistance Level
- KOD $9.14
- PSBD $16.07
- Average True Range (ATR)
- KOD 0.86
- PSBD 0.42
- MACD
- KOD -0.33
- PSBD 0.06
- Stochastic Oscillator
- KOD 15.73
- PSBD 61.76
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
About PSBD Palmer Square Capital BDC Inc.
Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.